Financial Summary


Array BioPharma Inc.

Array BioPharma Inc. (ARRY)

46.57 €
17.69 (+61.25%)
Neutral
B+
Market Info
Financial Info
Financial Modelling
Symbol ARRY
Price 46.57$
Beta 1.44
Volume Avrg. 3.00M
Market Cap 9.24B
Shares (2018) 198,490.00K
Last Div 0
Dividend Yield -
DCF Unlevered -16.84 Strong Sell
DCF Levered -19.08 Strong Sell
ROE -67.03% Strong Sell
ROA -32.00% Strong Sell
Operating Margin -74.77% Strong Sell
Debt / Equity 109.50% Buy
P/E -22.03 Strong Sell
P/B 14.77 Strong Buy

Income Statement

Quarter data

Balance Sheet Statement

Quarter data
Year 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Short-term debt ----0.15----12.602.50
Other Assets -----------
Total current liabilities 34.4150.3077.9369.8175.9450.5852.7342.4252.4369.5595.93
Cash and cash equivalents 56.4533.2032.8548.1055.8060.7468.5955.6956.60125.93114.75
Long-term debt 2.251.951.722.3192.1199.02103.95107.28113.66121.3193.38
Cash and short-term investments 95.6940.50111.5164.0833.38108.24111.00178.33109.94234.32412.49
Total debt 35.3583.17112.8391.5492.2699.02103.95107.28113.66121.3195.88
Inventories -----------
Deferred revenue 5.9911.2352.4747.8742.3414.356.198.9512.8617.1612.35
Goodwill and Intangible Assets -----------
Total non-current liabilities 3.002.422.526.53117.94107.32112.04113.13154.40197.87144.69
Total non-current assets 69.4033.79100.0831.6814.9714.6817.387.1613.608.978.82
Total liabilities 90.64118.46197.93150.42193.88157.90164.77155.55206.83267.42240.62
Total assets 62.3250.1441.8818.81108.07135.99139.05198.21168.90279.14460.36
Other comprehensive income 39.92---484.84610.65692.08751.07763.32930.331,319.99
Short-term investments 39.247.3078.6615.9933.3847.5142.41122.6453.34108.39297.74
Property, Plant & Equipment Net 30.1626.5021.4115.7012.0610.058.165.056.688.137.13
Net Debt -21.0949.9779.9843.4492.2638.2835.3651.5957.06-4.63-18.87
Investments 78.4914.59157.3331.9733.8547.9743.05123.1353.94109.12298.66
Total shareholders equity 38.03-73.70-116.68-130.86-85.81-21.91-25.7242.65-37.9311.73219.74
Retained earnings (deficit) -----570.74-632.68-717.94-708.57-801.41-918.70-1,100.00
Long-term investments 39.247.3078.6615.990.470.470.640.500.600.730.92
Receivables -----9.605.436.3139.3031.2832.08
Payables 4.666.485.634.466.475.406.954.5710.158.6414.06
Total current assets 100.7544.92117.3070.5693.11121.31121.68191.05155.30270.18451.54

Cash Flow Statement

Quarter data
Year 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
Operating Cash Flow -45.74-92.9417.56-65.94-33.55-87.07-71.68-5.79-70.09-39.40-119.78
Free Cash Flow -45.57-92.9417.56-65.94-34.98-89.41-74.30-8.30-73.25-42.92-121.02
Capital Expenditure -0.17---1.442.342.612.513.163.521.23
Depreciation & Amortization 6.106.616.347.625.088.839.769.507.909.538.49
Acquisitions and disposals -----------
Deferred income taxes -----------
Investment purchases -71.59-19.14-78.78-53.04-51.34-110.72-95.60-202.91-139.15-387.55-442.60
Accounts payables -1.741.81-1.06-0.582.01-1.321.87-1.113.93-1.005.72
Sales/Maturities of investments 130.5051.0810.97129.0134.0596.70100.70143.62208.34332.43252.80
Change in working capital 38.2922.3283.48-20.56-17.39-37.40-0.52-32.477.5657.90-0.08
Debt repayment ---6.34-4.35-92.71-0.09---14.55-4.31
Other non-cash items -----------
Investing Cash Flow 50.7329.00-69.0674.07-18.72-16.362.48-58.0566.03-58.12-191.04
Cash at beginning of period 10.6756.4533.2032.8548.1055.8060.7468.5955.6956.60125.93
Stock-based compensation 6.165.955.373.332.353.454.337.817.289.9619.11
Net cash flow / Change in cash 45.78-23.25-0.3615.257.704.947.86-12.900.9169.33-11.19
Effect of forex changes on cash -----------
Financing Cash Flow 40.7940.6951.157.1259.97108.3777.0650.944.97166.81299.63
Dividend payments -----------
Accounts receivables ------8.524.17-7.59-32.998.02-0.81
Cash at end of period 56.4533.2032.8548.1055.8060.7468.5955.6956.60125.93114.75
Net cash provided by operating activities -45.74-92.9417.56-65.94-33.55-87.07-71.68-5.79-70.09-39.40-119.78
Other working capital 40.0320.5084.54-19.98-19.40-27.56-6.55-23.7736.6350.88-4.99
Inventory -----------

Retained Earning Schedule

Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Retained Earnings (Previous Year) ------571-633-718-709-801-919
Net Income -96-128-78-56-24-62-859-93-117-147
Stock Dividends 961287856-547-----0-34
Dividend Paid -----------
Retained Earnings -----571-633-718-709-801-919-1,100

PPE Schedule

Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Gross PPE 283026211612108578
Annual Depreciation 2-4-5-6-5-4-5-6-2-2-2
Capital Expenditure -0---1233341
Net PPE 30262116121085787

Intangible and Goodwill Schedule

Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Intangible and Goodwill (Previous Year) -----------
New Purchases -72-19-79-53-51-111-96-203-139-388-443
Intangible and Goodwill -----------

About


Ron Squarer
Healthcare
Biotechnology
NASDAQ Global Market

Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.